Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights
Current Oncology Reports · 2025-01 · 27 (1) · 15-29
DOI: 10.1007/s11912-024-01626-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology Reports, online erschienen am 03.01.2025. Verfasst von Yu Aoki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tokyo Saiseikai Central Hospital, Minato-Ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Adenocarcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 97 Literaturangaben.
Abstract (Originalsprache)
PURPOSE OF REVIEW: Human epidermal growth factor receptor 2 (HER2) is a critical target in advanced gastric cancer (AGC). This review highlights the current treatment landscape, lessons learned from past clinical trials, and prospects for future treatment strategies for HER2-positive AGC. RECENT FINDINGS: Trastuzumab had been the standard treatment for HER2-positive AGC for a decade, and subsequently, trastuzumab deruxtecan, an antibody-drug conjugate (ADC), emerged with an impressive response. Recently, the addition of pembrolizumab to first-line chemotherapy plus trastuzumab has become a novel standard treatment. Past clinical trials of HER2-targeted therapies, which succeeded in HER2-positive breast cancer but failed in AGC, have deepened our understanding of resistance mechanisms. Based on these results, several clinical trials of novel HER2-targeted therapies, including immunologic approaches such as CAR-T cells and vaccines, are currently ongoing. Circulating tumor DNA is also expected to be a tool for real-time biomarker analysis. Additionally, ADCs with a bystander effect have the potential to expand the scope of HER2-targeted therapies to HER2-expressing, including HER2-low AGC. Learning from past trials, further development of novel HER2-targeted therapies is underway, expanding their scope to HER2-expressing AGC. Meanwhile, selecting optimal treatment is a challenging issue in cases with HER2-low AGC overlapping with other biomarkers like CLDN18.2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Tokyo Saiseikai Central Hospital, Minato-Ku, Tokyo, Japan.
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa City, Chiba, Japan.
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa City, Chiba, Japan. iznakaya@east.ncc.go.jp.
Zitieren
APA
Aoki, Y., Nakayama, I., & Shitara, K. (2025). Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights. Current Oncology Reports, 27(1), 15-29. https://doi.org/10.1007/s11912-024-01626-2
Vancouver
Aoki Y, Nakayama I, Shitara K. Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights. Current Oncology Reports. 2025;27(1):15-29. doi:10.1007/s11912-024-01626-2
BibTeX
@article{Aoki2025,
author = {Aoki, Yu and Nakayama, Izuma and Shitara, Kohei},
title = {Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights},
journal = {Current Oncology Reports},
year = {2025},
volume = {27},
number = {1},
pages = {15--29},
doi = {10.1007/s11912-024-01626-2}
}
EUVIMED